Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cyclacel Pharmaceuticals, Inc. (UXI4.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.4760-0.0295 (-5.84%)
At close: 09:50PM CEST
Advertisement
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.
Currency in EUR

Valuation Measures4

Yahoo Finance Plus required to access annual data
Annual
Quarterly
Yahoo Finance Plus required to access monthly data
Monthly
Subscribe to Yahoo Finance Plus Essential to download historical data
 
As of Date: 4/1/2023
Current
Market Cap (intraday)
N/A
Enterprise Value
N/A
Trailing P/E
N/A
Forward P/E
N/A
PEG Ratio (5 yr expected)
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
N/A
Enterprise Value/Revenue
N/A
Enterprise Value/EBITDA
N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 1.16
52-Week Change 3N/A
S&P500 52-Week Change 3N/A
52 Week High 32.7740
52 Week Low 30.4666
50-Day Moving Average 30.7346
200-Day Moving Average 31.0526

Share Statistics

Avg Vol (3 month) 3N/A
Avg Vol (10 day) 3N/A
Shares Outstanding 512.54M
Implied Shares Outstanding 6N/A
Float 810.83M
% Held by Insiders 14.63%
% Held by Institutions 133.09%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:20
Last Split Date 3Apr 15, 2020

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec 31, 2021
Most Recent Quarter (mrq)Sep 30, 2022

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-41.67%
Return on Equity (ttm)-60.14%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-338k
EBITDA -25.31M
Net Income Avi to Common (ttm)-19.27M
Diluted EPS (ttm)-2.8430
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)23.71M
Total Cash Per Share (mrq)1.89
Total Debt (mrq)107k
Total Debt/Equity (mrq)0.49
Current Ratio (mrq)6.41
Book Value Per Share (mrq)5.32

Cash Flow Statement

Operating Cash Flow (ttm)-20.21M
Levered Free Cash Flow (ttm)-14.69M
Advertisement
Advertisement